logo
‘Pay us what you owe us': America divided by WNBA T-shirt stunt

‘Pay us what you owe us': America divided by WNBA T-shirt stunt

News.com.aua day ago
WNBA stars have sparked widespread divide by wearing T-shirts with 'pay us what you owe us' emblazed on the front.
The blunt message was delivered during warm ups ahead of the WNBA All Star Game on Sunday amid ongoing collective bargaining agreement negotiations between the players and the league.
With a late October deadline looming, the players' stance is clear … they want a bigger piece of the pie.
It's not the first time WNBA players have demanded more pay, with the talking point rearing its head every year.
The latest act however comes off the back of the league agreeing to an 11-year, $AUD3.38 billion TV rights deal with Disney, Amazon Prime Video and NBCUniversal that will come into play from 2026.
The WNBA is booming with TV ratings (up 23%), ticket sales (up 26%) and attendance (13%) all surging halfway through the season, according to NPR.
But the simple act of wearing a T-shirts demanding to be paid more sparked widespread divide with many believing the players are deserving of greater pay, while countless others pointed to the league's struggling finances which have seen the WNBA never make a profit.
What is the WNBA's revenue?
That's the big talking point behind all of the ongoing CBA negotiations, the WNBA players are chasing a large share of the league's revenue.
Under the current CBA, the players split 9.3 per cent of league revenue. A figure far lesser than the NBA which sees players split between 49 and 51 per cent.
The league currently operates off a revenue of $200m, but as is often pointed out when these discussions come to the table … the WNBA has yet to turn a profit since its inception in 1996.
The NBA owns nearly 60 per cent of the league with team owners investing millions every year to the WNBA.
Despite the recent uptick, the 2024 WNBA season saw the league lose $40 million.
The new TV rights deal will inject $200m annually into the league, compared to the current deal which injects roughly $45m per season.
With that deal set to come into play from 2026 onwards, WNBA players could soon see their salaries rise and the league turn a profit for the first time.
What is the difference in WNBA and NBA salaries?
According to Sports Illustrated, WNBA salaries roughly range from a minimum of $USD66,000 to a super maximum contract of around $USD250,000.
Despite being the face of the league, Caitlin Clark remains on a rookie contract which will see her earn $78,000 in 2025.
Compare those figures to the NBA and the difference is eye-watering.
The average NBA salary for the 2024-25 season was projected to be $11,910,649, according to SI.
The minimum salary came in at $1,157,153 while the highest-paid player, Stephen Curry, earned a staggering $55.7 million.
America divided by players calling for more pay
You can almost guarantee that anytime a WNBA player speaks out about wanting to be paid more, social media will be flooded with vitriol
It kicked into overdrive on Sunday as images of the players wearing the shirts began to spread across the internet.
End Wokeness wrote on X: 'The WNBA loses $50 million every year and has NEVER generated a profit. You deserve $0.00.'
Jake Crain added: 'There is no league as tone deaf as the WNBA. 'Pay us what you owe us' shirts when you have to be subsidised is wild.'
Fox Sports Radio host Aaron Torres wrote: 'There is no group of more delusional people on planet Earth, than WNBA players.'
Of course not everyone was on the side of the corporation with a plethora of fans backing the players in chasing what they're worth.
WTH News wrote: 'They're not asking for NBA bags, just their damn slice of the pie. Talent's on the court, money's on the table — time to match the energy. You don't build a league on players and leave them crumbs.'
NBA and WNBA beat reporter Andrew Dukowitz wrote: 'The league is built on players, they deserve to get a bigger slice of the pie for the work they all have put in, and as the revenue grows, they should as well. The WNBA players are not asking to be paid dollar for dollar what the NBA players make, from what I understand they just want a fair share of the revenue.'
Barstool Sports' Dave Portnoy took his outrage even further, savaging people who don't believe the WNBA players don't deserve a bigger slice.
'I don't know how anybody in the world with a brain, and maybe my brain is just bigger than most, can rationally say women don't deserve more money at this point,' Portnoy said in a video posted to social media.
'Franchise values are exploding. Ticket sales, merch, TV rights all exploding. The players have an opt out in their CBA. Of course they took it. It's all about leverage in re-negotiations and for the 1st time in history of the league players have power.
'The players make virtually nothing while the entire league explodes. Of course they deserve more money.'
What will it mean if no agreement is reached?
With the first round of talks going almost nowhere, the threat of a potential player lockout remains real.
The players union has said it's preparing for a work stoppage when the current CBA expires Oct. 31.
WNBA commissioner Cathy Engelbert said she has 'confidence' a deal can be struck before the Halloween deadline, but also said she's 'not going to put an exact date on it.
'We're in a good place and we're going back and forth,' she said.
If no agreement is reached, the players will effectively not turn up to work until a deal is struck which could then have an impact on the upcoming expansion drafts in December.
Free agency, which usually starts in late January, and potentially the April draft would also be on hold as long as a deal remains unfinalised.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Health Check: Bug buster Genetic Signatures' US expansion is a jumbo-sized task
Health Check: Bug buster Genetic Signatures' US expansion is a jumbo-sized task

News.com.au

time11 hours ago

  • News.com.au

Health Check: Bug buster Genetic Signatures' US expansion is a jumbo-sized task

Genetic's company-making US expansion proves harder than expected BTC Health makes a (literally) lifesaving sale The lessons from Sarepta's billion-dollar FDA woes Gut disease diagnostics provider Genetic Signatures (ASX:GSS) is finding its US market entry more elephantine than first envisaged and has made some changes 'to better align with current strategy and needs'. On June 4 last year the US Food and Drug Administration (FDA) approved Genetic's Easyscreen, which can detect eight gastrointestinal (GI) parasites accounting for 90% of all tummy bugs. On the same day the company launched a $30 million capital raise to support the US push and announced a new CEO (former Roche Diagnostics exec Allison Rossiter). Genetic expected to be selling in the US within 60 to 90 days. Today, Genetic says the US sales ramp-up has been 'impacted by prospective customers' internal processes, competing priorities, preference for enhanced workflow and uncertainty in the US healthcare environment.' In part, the company discovered that clients craved more automated sample processing. In response, Genetic has entered a three-way 'strategic partnership' with a mob called Tecan (lab automation) and Repado (compliant in vitro diagnostics). This threesome will result in a 'scalable suite of fully automated diagnostic platforms for syndromic testing labs'. Genetic doesn't mention any dollars, so we presume the financial impact is immaterial. Speaking of finances, Genetic today reported June quarter sales of $4.4 million. This was 52% higher than the March stanza, reflecting higher seasonal testing during the Australian flu season. But turnover was flat on a year-on-year comp. Having expended a net $5.95 million, Genetic ended the quarter with still-healthy cash of $30.9 million. Microba GI testing sales are on tract Still on tummy bugs, microbiome testing outfit Microba Life Sciences (ASX:MAP) has met its guidance with full-year revenue of $15.67 million, 30% higher year on year. June (fourth) quarter revenue fell 13.5% to $4.2 million, the result of the company shedding a non-core research services business. Microba has commercialised two clinical tests, to assess and manage GI patients. The flagship Metaxplore tests assess a range of markers to appraise the GI tract and presents the results in a clear report. Metapanel is the 'first line' test to determine whether the patient has a pathogen that can be treated simply with antibiotics. Currently Metaxplore is sold in Australia and the UK, while Metapanel is available locally via the company's partner and biggest shareholder, Sonic Healthcare (ASX:SHL). Microba chief Dr Luke Reid says Microba has a 'well considered plan' for US rollout, based on creating a beachhead in one city. Mayne they could swap notes with Genetic's management. Locally Microba sold 3451 Metaexplore tests during the quarter, up 88%. Microba also sold 266 Metapanel tests here (up 85%) and 429 in the UK (the test was only launched there in May). Microba recorded net cash outflows of $5.56 million for the quarter, but management affirms the Australian and UK ops should be break-even this year. BTC Health's PDF format suits investors One of the more unusual life science plays on the bourse, medical product distributor BTC Health (ASX:BTC) has secured a $500,000 equipment order with Adelaide's Women's and Children's Hospital. The order is for extracorporeal membrane oxygenation (ECMO) and follows a similar deal with Melbourne's Royal Children's Hospital. ECMOs take over the work of the heart and lungs when these organs cannot perform their duties. BTC Health is building a portfolio of diverse yet specialist medical devices, such as heart valves and infusion pumps. BTC is a valuable pooled development fund (PDF), a remnant of a Keating-era initiative to bolster investment in small business. PDFs pay only 15% tax on income and capital gains, but any returns to shareholders are tax free. Only 17 PFDs remain and – like coastal property – God is not creating any more of them. BTC chief Dr Richard Treagus previously headed generic drug play Acrux, the sector's only other PDF. BTC posted December half revenue of $5.3 million, with underlying earnings of $200,000. The company expects to have remained in the black for the full year to June 30 with a 'pathway to sustainable growth'. Sarepta 'is worth nothing' Could a $US1.31 billion company really be worth nothing? US investment bank H.C. Wainwright thinks so, having ascribed a 'price target' of yada and zip to the Sarepta Therapeutics on the back of the Nasdaq-listed entity's drug strife. Last week the FDA asked Sarepta to voluntarily halt shipments of its Elevidys gene therapy, for muscular dystrophy. This follows the death of two patients from liver toxicity issues and the third from a separate experimental gene therapy treatment. Defying the agency, Sarepta said it would continue to ship the therapy to ambulatory patients, but maintain a halt for wheelchair-bound ones. The deaths pertained to the latter. The FDA approved Elevidys two years ago for walking patients aged four or older, with the Duchenne muscular dystrophy (DMD) gene mutation. A year later the agency expanded the assent to non-ambulatory patients. Sarepta shares shed up to 40% on Friday and a further 5% overnight. Don't fight City Hall H.C. Wainwright previously had a US$10 valuation on Sarepta, compared with the stock's overnight close of US$13.32. The firm describes Sarepta's fight with the FDA as 'unwinnable' and – indeed – you can't beat City Hall. Elevidys generated US$384 million of net revenue in the December quarter, more than half of Sarepta's total revenue of US$638 million. The lesson for everyone is that even when drug makers have done the hard yards of developing and commercialising a therapy, success is still not guaranteed. In one of the best-known cases, in 1999 the FDA approved Merck's Vioxx, for osteoarthritis pain. After racking up billions in sales Merck withdrew the drug from sale in 2004, amid concerns it could cause heart attacks and strokes. Locally, Percheron Therapeutics (ASX:PER) is reinventing itself after its DMD therapy failed in phase IIb stage last December. Perhaps the company dodged a bullet by discovering the problems early in the piece, but wounded investors might disagree.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store